Eli Lilly | LLY - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Abbott USD 10.46B 1.15B 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Drreddys Laboratories INR 74.33B 1.4B 2026-03
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
J&J USD 17.83B 388M 2026-06
Medtronic USD 7.72B 436M 2026-03
Merck USD 15.77B 2.4B 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Novartis USD 9.29B 507M 2026-03
Novo Nordisk DKK 44.73B 7.52B 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 213.19M 7.06M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.92B 607M 2026-06
Sanofi EUR 8.98B 1.73B 2026-03
United Therapeutics USD 6.4B 499.2M 2026-06
Zoetis USD 3.15B 85M 2026-06